162 related articles for article (PubMed ID: 36210027)
41. Allogeneic peripheral blood stem cell transplantation with CD34+-cell selection and delayed T-cell add-back in adults. Results of a single center pilot study.
Martino R; Martín-Henao G; Sureda A; Altés A; Canals C; Brunet S; Sierra J
Haematologica; 2000 Nov; 85(11):1165-71. PubMed ID: 11064469
[TBL] [Abstract][Full Text] [Related]
42. Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation.
Prabahran A; Koldej R; Chee L; Ritchie D
Blood Adv; 2022 Mar; 6(6):1947-1959. PubMed ID: 34492685
[TBL] [Abstract][Full Text] [Related]
43. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
[TBL] [Abstract][Full Text] [Related]
44. Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation.
Lickliter JD; McGlave PB; DeFor TE; Miller JS; Ramsay NK; Verfaillie CM; Burns LJ; Wagner JE; Eastlund T; Dusenbery K; Weisdorf DJ
Bone Marrow Transplant; 2000 Oct; 26(7):723-8. PubMed ID: 11042652
[TBL] [Abstract][Full Text] [Related]
45. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
46. Allogeneic transplantation of peripheral blood stem cell grafts results in a massive decrease of primitive hematopoietic progenitor frequencies in reconstituted bone marrows.
Kordelas L; Görgens A; Radtke S; Horn PA; Beelen DW; Giebel B
Bone Marrow Transplant; 2020 Jan; 55(1):100-109. PubMed ID: 31435034
[TBL] [Abstract][Full Text] [Related]
47. Long-term engraftment, graft-vs.-host disease, and immunologic reconstitution after experimental transplantation of allogeneic peripheral blood cells from G-CSF-treated donors.
Pan L; Bressler S; Cooke KR; Krenger W; Karandikar M; Ferrara JL
Biol Blood Marrow Transplant; 1996 Oct; 2(3):126-33. PubMed ID: 9199755
[TBL] [Abstract][Full Text] [Related]
48. A matched-pair analysis reveals marginally reduced CD34+ cell mobilization on second occasion in 27 related donors who underwent peripheral blood stem cell collection twice at the same institution.
Velier M; Granata A; Bramanti S; Calmels B; Furst S; Legrand F; Harbi S; Faucher C; Devillier R; Blaise D; Mfarrej B; Lemarie C; Chabannon C
Transfusion; 2019 Nov; 59(11):3442-3447. PubMed ID: 31625183
[TBL] [Abstract][Full Text] [Related]
49. Impact of Single-Dose Plerixafor as an Adjunct to Granulocyte Colony-Stimulating Factor-Based Peripheral Blood Stem Cell Mobilization on the Graft Composition and Outcome for T Cell-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Comparative Study.
Jaiswal SR; Bhakuni P; Joy A; Murli N; Bharadwaj P; Zaman S; Nedunchezian M; Chakrabarti S
Biol Blood Marrow Transplant; 2018 Mar; 24(3):542-548. PubMed ID: 29191663
[TBL] [Abstract][Full Text] [Related]
50. Combined transplantation of allogeneic bone marrow and CD34+ blood cells.
Link H; Arseniev L; Bähre O; Berenson RJ; Battmer K; Kadar JG; Jacobs R; Casper J; Kühl J; Schubert J; Diedrich H; Poliwoda H
Blood; 1995 Oct; 86(7):2500-8. PubMed ID: 7545459
[TBL] [Abstract][Full Text] [Related]
51. Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants.
Kong Y; Song Y; Hu Y; Shi MM; Wang YT; Wang Y; Zhang XH; Xu LP; Liu KY; Deng HK; Huang XJ
Oncotarget; 2016 May; 7(21):30892-906. PubMed ID: 27105530
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation.
Prabahran A; Koldej R; Chee L; Wong E; Ritchie D
Leuk Lymphoma; 2021 Jun; 62(6):1482-1489. PubMed ID: 33522344
[TBL] [Abstract][Full Text] [Related]
53. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
54. Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation.
Min CK; Kim DW; Lee JW; Min WS; Kim CC
Acta Haematol; 2000; 104(4):185-92. PubMed ID: 11279309
[TBL] [Abstract][Full Text] [Related]
55. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.
Olsson RF; Logan BR; Chaudhury S; Zhu X; Akpek G; Bolwell BJ; Bredeson CN; Dvorak CC; Gupta V; Ho VT; Lazarus HM; Marks DI; Ringdén OT; Pasquini MC; Schriber JR; Cooke KR
Leukemia; 2015 Aug; 29(8):1754-62. PubMed ID: 25772027
[TBL] [Abstract][Full Text] [Related]
56. Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation.
Chen J; Wang H; Zhou J; Feng S
Ther Adv Hematol; 2020; 11():2040620720948743. PubMed ID: 32874483
[TBL] [Abstract][Full Text] [Related]
57. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies.
Brown RA; Adkins D; Goodnough LT; Haug JS; Todd G; Wehde M; Hendricks D; Ehlenbeck C; Laub L; DiPersio J
J Clin Oncol; 1997 Sep; 15(9):3067-74. PubMed ID: 9294469
[TBL] [Abstract][Full Text] [Related]
58. Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag.
Tang C; Chen F; Kong D; Ma Q; Dai H; Yin J; Li Z; Chen J; Zhu X; Mao X; Wu D; Tang X
J Hematol Oncol; 2018 Aug; 11(1):103. PubMed ID: 30115080
[TBL] [Abstract][Full Text] [Related]
59. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation.
Thomson BG; Robertson KA; Gowan D; Heilman D; Broxmeyer HE; Emanuel D; Kotylo P; Brahmi Z; Smith FO
Blood; 2000 Oct; 96(8):2703-11. PubMed ID: 11023501
[TBL] [Abstract][Full Text] [Related]
60. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood.
Urbano-Ispizua A; Rozman C; Martínez C; Marín P; Briones J; Rovira M; Féliz P; Viguria MC; Merino A; Sierra J; Mazzara R; Carreras E; Montserrat E
Blood; 1997 Jun; 89(11):3967-73. PubMed ID: 9166834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
